Examination of Tumor Regression Grading Systems in Breast Cancer Patients Who Received Neoadjuvant Therapy.

Pathology Oncology Research : POR
Anita SejbenTamás Zombori

Abstract

Neoadjuvant therapy is a common form of treatment in locally advanced breast cancer (LABC) patients. Besides some guidelines for grading regression, a standardized general scheme is not yet available. The aim of our study was to compare the prognostic impact of different regression grading systems, namely the TR/NR, Chevallier, Sataloff, Denkert-Sinn, Miller-Payne, NSABP-B18, Residual Disease in Breast and Nodes and Residual Cancer Burden (RCB) on disease-free (DFS) and overall survival (OS). Data of 746 breast cancer patients treated in neoadjuvant setting between 1999 and 2019 have been included. The different regression grades and follow-up data were collected from medical charts. Statistical analysis included the Kaplan-Meier method, log-rank test and multivariate Cox regression. The average patient age was 55 years. The DFS and OS estimates of patients with complete pathological regression and residual in situ carcinoma have been significantly more favorable than those having partial regression or no signs of regression (pDFS<0.001, pOS < 0.001). Significant differences were found between DFS estimates of classes with partial regression and without regression defined by RCB. Concerning DFS estimates, the RCB classification...Continue Reading

References

Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B ChevallierC Fizames
Dec 6, 2003·The Oncologist·Sharon H Giordano
Dec 9, 2003·The Breast : Official Journal of the European Society of Mastology·Keith N OgstonSteven D Heys
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansLajos Pusztai
Nov 14, 2007·Journal of Cancer Research and Therapeutics·Ashish RustogiRakesh Jalali
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Sep 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M Thompson, S L Moulder-Thompson
Oct 4, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleftherios P MamounasNorman Wolmark
Jun 19, 2013·International Journal of Applied & Basic Medical Research·Divya SethiJyotsna Sen
May 6, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S CoatesUNKNOWN Panel Members
Jul 25, 2015·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Elena ProvenzanoUNKNOWN Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collabo
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E SenkusUNKNOWN ESMO Guidelines Committee
Apr 14, 2016·Journal of Pathology and Translational Medicine·Cheol Keun ParkJa Seung Koo
Jan 31, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansGabriel N Hortobagyi
Oct 19, 2017·Radiology·Amy M FowlerBonnie N Joe

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
surgical resection
dissection
imaging techniques

Software Mentioned

SPSS Statistics

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.